Biocon up on siRNA deal

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) partnered with Quark Pharmaceuticals Inc. to co-develop therapeutics using Quark's short interfering RNA technology. Under the deal, Biocon gains rights to co-develop and commercialize Quark's QPI-1007 in India and other undisclosed markets. QPI-1007, an siRNA that inhibits expression of caspase 2 (CASP2), has completed a Phase I/IIa trial to treat non-arteritic anterior ischemic optic neuropathy (NA-AION). The partners will also co-develop additional siRNA products for undisclosed conditions. Financial terms were not disclosed. ...